Immunome Inc. (NASDAQ: IMNM) director Isaac Barchas has executed a substantial reduction in his holdings, selling a total of 100,000 shares of the company's common stock. The transactions, which were filed with the Securities and Exchange Commission via Form 4, occurred on July 6 and July 7, 2026. The aggregate value of these sales reached approximately $2,412,521, with the shares changing hands at prices ranging from $24.11 to $24.20 per share.
The sales were carried out through AMBHMC II LLC, a vehicle in which Mr. Barchas serves as a managing member. He holds a power of attorney that grants him the authority to exercise voting and investment decisions regarding the shares held by the LLC. Despite this control, Mr. Barchas disclaims beneficial ownership of these specific shares, limiting his claim to only his pecuniary interest. Following the liquidation of these 100,000 shares, Mr. Barchas continues to indirectly hold 108,504 shares through AMBHMC II LLC. Furthermore, he maintains a direct ownership stake of 103,259 shares of Immunome common stock.
The initial transaction on July 6 involved the disposal of 83,094 shares. These shares were sold at a weighted average price of $24.11, with individual sale prices fluctuating between $24.00 and $24.29. The subsequent transaction on July 7 saw the sale of an additional 16,906 shares. These were disposed of at a weighted average price of $24.20, with prices for this batch varying between $24.00 and $24.58. Both sets of trades were executed automatically under a Rule 10b5-1 trading plan that was established by AMBHMC II LLC on March 31, 2026.
This insider activity occurs against a backdrop of significant stock price appreciation. Over the past year, Immunome's shares have surged approximately 181%, climbing from a 52-week low of $7.96. According to analysis provided by InvestingPro, the stock currently appears overvalued relative to its calculated Fair Value. This valuation metric may offer context for the director's decision to reduce his holdings, although the automated nature of the sales via a pre-arranged plan suggests the timing was predetermined.
Recent corporate developments have also been prominent for the biotech firm. Immunome announced the dosing of the first patient in a Phase 1 trial for IM-1617, an antibody-drug conjugate designed to treat solid tumors. This trial is set to evaluate the safety and effectiveness of the treatment across various phases. Additionally, the company presented promising results from a Phase 3 trial for its desmoid tumor drug, varegacestat, at a major oncology meeting. The data demonstrated an 84% reduction in the risk of disease progression or death compared to a placebo. Consequently, Immunome has submitted a New Drug Application to the U.S. Food and Drug Administration for varegacestat, seeking approval for the treatment of desmoid tumors.
Wall Street has responded to these advancements with optimism. Truist Securities raised its price target for Immunome to $37, maintaining a Buy rating. Truist cited the drug's efficacy and safety profile as primary drivers for the upgrade. Similarly, Barclays initiated coverage of Immunome with an overweight rating and a price target of $36, reflecting confidence in the company's potential market impact.